Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
third dose
Description:
An additional vaccine dose administered after an initial vaccination series, often to strengthen or renew immune protection.
Primary topic:
SARS-CoV-2 and COVID-19 Research (75%)
Related topics:
SARS-CoV-2 and COVID-19 Research (75%),
Vaccine Coverage and Hesitancy (11%)
OpenAlex ID:
keywords/third-dose
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
2021
·
Noam Barda
, Noa Dagan
, et al.
·
The Lancet
·
916
PDF
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
2021
·
Alasdair P S Munro
, Leila Janani
, et al.
·
The Lancet
·
715
PDF
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
2022
·
Mark G. Thompson
, Karthik Natarajan
, et al.
·
MMWR Morbidity and Mortality Weekly Report
·
434
PDF
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
2022
·
Edson D. Moreira
, Nicholas Kitchin
, et al.
·
New England Journal of Medicine
·
380
PDF
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
2021
·
Gang Zeng
, Qianhui Wu
, et al.
·
The Lancet Infectious Diseases
·
342
PDF
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
2021
·
Amy Flaxman
, Natalie G Marchevsky
, et al.
·
The Lancet
·
267
PDF
Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study
2022
·
Julia Stowe
, Nick Andrews
, et al.
·
Nature Communications
·
162
PDF
Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
2021
·
Yunlong Cao
, Ayijiang Yisimayi
, et al.
·
Cell Research
·
147
PDF
Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients
2021
·
Arnaud Del Bello
, Florence Abravanel
, et al.
·
American Journal of Transplantation
·
133
Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series
2022
·
Sophie Caillard
, Olivier Thaunat
, et al.
·
Annals of Internal Medicine
·
122
PDF
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
2023
·
Flor M. Muñoz
, Lawrence D. Sher
, et al.
·
New England Journal of Medicine
·
111
PDF
Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study
2021
·
Sara Y. Tartof
, Jeff M. Slezak
, et al.
·
The Lancet Regional Health - Americas
·
111
PDF
Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
2022
·
Hongjie Xia
, Jing Zou
, et al.
·
Cell Host & Microbe
·
105
Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021
2021
·
Anne M. Hause
, James Baggs
, et al.
·
MMWR Morbidity and Mortality Weekly Report
·
93
PDF
CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
2022
·
Lairun Jin
, Zhuopei Li
, et al.
·
Human Vaccines & Immunotherapeutics
·
92
Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study
2022
·
Susana Monge
, Ayelén Rojas-Benedicto
, et al.
·
The Lancet Infectious Diseases
·
90
Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary
2021
·
Marie Tré-Hardy
, Roberto Cupaiolo
, et al.
·
Journal of Infection
·
87
PDF
COVID-19 vaccine equity and booster doses
2021
·
The Lancet Infectious Diseases
·
The Lancet Infectious Diseases
·
85
PDF
Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques
2002
·
M ZHANG
, Suzanne U Emerson
, et al.
·
Vaccine
·
84
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
2021
·
Jiwon Jung
, Heungsup Sung
, et al.
·
New England Journal of Medicine
·
80
Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine
2021
·
Yaki Saciuk
, Jennifer Kertes
, et al.
·
The Journal of Infectious Diseases
·
78
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses
2022
·
Hope R Lapointe
, Francis Mwimanzi
, et al.
·
The Journal of Infectious Diseases
·
75
PDF
Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults
2022
·
Addi J. Romero-Olmedo
, Axel Ronald Schulz
, et al.
·
Nature Microbiology
·
71
PDF
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
2022
·
Xinxue Liu
, Alasdair P S Munro
, et al.
·
Journal of Infection
·
70
PDF
SARS‐CoV‐2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two‐dose CoronaVac vaccine regimen
2021
·
Ali Umit Keskin
, Sibel Bolukcu
, et al.
·
Journal of Medical Virology
·
67
Show more works
View as search
Works count:
525
Citation count:
8,221
Year
Topic
Type